Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents

NCT01691430 · View on ClinicalTrials.gov ↗

Study Summary

Urinary tract infection (UTI) is the most common infection in nursing home residents, and bacteriuria is the greatest trigger for antimicrobial therapy in the nursing home setting. The primary aim of this study is to test the efficacy of two oral cranberry capsules per day in the reduction of bacteriuria plus pyuria in female nursing home residents. These aims will be accomplished by conducting a double blind randomized placebo controlled efficacy trial of two oral cranberry capsules daily versus placebo in a cohort of Connecticut female nursing home residents.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT 2 cranberry capsules

Study Locations (20)

Connecticut

  • Branford Hills Health Care — Branford
  • Northbridge Health Care Center — Bridgeport
  • Bridgeport Health Care Center — Bridgeport
  • Bridgeport Manor — Bridgeport
  • Riverside Health & Rehabilitation Center — East Hartford
  • Ludlowe Health Care Center — Fairfield
  • Glastonbury Health Care Center — Glastonbury
  • The Nathaniel Witherell — Greenwich
  • Arden House Care and Rehabilitation Center — Hamden
  • Hamden Health Care Center — Hamden
  • Avery Heights — Hartford
  • Wadsworth Glen Health Care and Rehabilitation Center — Middletown
  • Water's Edge Center for Health & Rehabilitation — Middletown
  • Grimes Center — New Haven
  • Mary Wade Home — New Haven
  • Advanced Nursing & Rehab Center of New Haven — New Haven
  • Shady Knoll Health Center — Seymour
  • Lord Chamberlain Nursing & Rehabilitation Center — Stratford
  • Village Green of Wallingford — Wallingford
  • Abbott Terrace Health Center — Waterbury

Trial Details

FieldValue
Enrollment Target 185 participants
Start Date 2012-08
Est. Completion 2015-10
Phase Phase 3

Sponsor

Yale University

1,283 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01691430

The ClinicalTrials.gov registry entry for NCT01691430 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,283 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Bacteriuria appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01691430 reports 20 study locations spanning 1 distinct geographic area — top geographies include Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01691430 about?

NCT01691430 is a clinical study titled "A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents". Urinary tract infection (UTI) is the most common infection in nursing home residents, and bacteriuria is the greatest trigger for antimicrobial therapy in the nursing home setting. The primary aim of this study is to test the efficacy of two oral cranberry capsules per day in the reduction of bacter...

What is the current status of trial NCT01691430?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2012-08. Estimated completion is 2015-10.

What conditions does trial NCT01691430 study?

This clinical trial studies the following conditions: Bacteriuria. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01691430?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), 2 cranberry capsules (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01691430?

This trial is sponsored by Yale University, which has 1,283 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01691430 being conducted?

This trial has 20 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial